Over the past several months, we conducted in depth research calls with analytical development leaders, CMC strategists, regulatory reviewers, and bioassay specialists across global pharma, emerging biotechs, and regulatory agencies. These discussions explored challenges spanning potency assay development, DAR characterization, impurity profiling, method transfer, regulatory ambiguity, and the increasing analytical burden created by next generation modalities including bispecific, hydrophilic, and dual payload ADCs.
Across more than 20 hours of expert dialogue, several clear scientific and regulatory priorities emerged that now define the strategic direction of ADC analytical development in 2026. What follows is a summary of these themes and how they directly guided the development of the 5th ADC Analytical Development Summit agenda.
Controlling & Understanding Impurities Remains the Most Pressing Analytical Challenge
Impurities, both conjugatable and non-conjugatable, remain the most frequently cited bottleneck across analytical teams. Experts consistently emphasized that impurity species behave unpredictably in vivo and in toxicology studies, and that the industry still lacks sufficiently advanced tools, data, and harmonized regulatory expectations to manage them with confidence.
A persistent gap exists between theoretical understanding and real-world impurity behaviour, particularly in later clinical stages when minor species may carry outsized regulatory risk. Developers continue to struggle with setting meaningful acceptance limits for small molecule linker impurities and free drug impurities, especially when toxicological relevance is unclear. Compounding this issue is the lack of harmonized expectations across global regulatory agencies for impurity specifications, forcing companies to justify decisions case by case.
Analytically, identifying and characterizing payload derived degradants remains especially difficult. Small molecule fragments are often masked beneath the antibody’s intact mass signal, limiting visibility and delaying root cause analysis. As a result, there is growing demand for robust late-stage case studies, improved tools to detect and quantify small molecule degradants, stronger frameworks to assess clinical relevance, and broader industry discussion around acceptable specification setting. Impurity control remains foundational to safety assessment, CMC strategy, and late stage filing success.
Regulatory Expectations Are Increasingly Complex, Case by Case, & Globally Divergent
A major theme across conversations was the lack of clear and harmonized regulatory guidance specific to ADC analytics, particularly for emerging modalities. Experts reported conflicting interpretations across regions, shifting expectations across development phases, and ongoing uncertainty about what constitutes “sufficient” characterization at each stage of development.
Divergent expectations between agencies such as the FDA, EMA, PMDA, and others create strategic tension when setting impurity limits, charge variant specifications, and potency assay requirements. Because there is no dedicated ADC specific global framework, regulators frequently fall back on general ICH guidance not originally designed for conjugated biologics. This results in ambiguity when defining late-stage specifications and uncertainty about whether cell-based assays must be introduced as early as Phase 1 or can be implemented later without regulatory risk.
Teams repeatedly expressed a need for clearer agency communication, greater transparency into evolving expectations, and more opportunities to benchmark strategies with peers. These regulatory complexities heavily informed the structure of this year’s agenda.
Implementing Advanced Analytical Methods, Especially MS Based Approaches, Is Critical but Not Widely Achieved
High resolution mass spectrometry, subunit analysis, native MS, and advanced chromatographic techniques offer significantly deeper insight than traditional UV based approaches. However, many organizations still struggle to integrate these technologies into routine workflows. Bandwidth limitations, lack of internal expertise, and the difficulty of embedding MS into QC environments were commonly cited barriers.
There is often a disconnect between early development teams who rely heavily on advanced MS characterization and late-stage clinical or QC teams who must operate within validated, simplified systems. Interpreting complex MS data for DAR distribution, degradant profiling, and conjugation chemistry adds further difficulty, particularly when regulatory validation requirements are unclear.
Experts are not seeking theoretical discussions but practical implementation strategies. They want clarity on when MS should replace UV or HPLC methods, how MS based assays can be validated for regulatory submissions, how to adopt new instrumentation without overwhelming QC teams, and real case studies demonstrating how MS insights altered development decisions.
Assay Development for New Modalities Has Become One of the Fastest Growing Burdens in Analytics
As ADC formats expand beyond traditional constructs to include bispecific ADCs, highly hydrophilic linker payload architectures, peptide linked ADCs, and dual payload molecules, analytical teams are facing an accelerating wave of complexity. Many experts described a lack of regulatory precedent for peptide linked and bispecific constructs, creating uncertainty in assay design and validation expectations.
Designing potency assays that accurately reflect multiple mechanisms of action presents additional difficulty, particularly when dual payload ADCs may require separate potency assessments for each warhead. Interpreting analytical outputs from highly complex constructs further strains existing frameworks for critical quality attribute selection and stability testing.
This evolution is compelling analytical teams to reassess foundational approaches to potency measurement, CQA prioritization, and stability strategy, directly shaping the design and focus of this year’s sessions.
Method Transfer to QC Environments Remains Exceptionally Difficult, Particularly for Cell Based Assays
Transferring analytical methods from development laboratories into QC environments continues to be a universal pain point, especially for potency assays and complex cell-based systems. Variability in cell lines, reagents, analyst skill level, and environmental factors often undermines robustness and reproducibility once assays leave their originating lab.
Global transfers add further complexity, with instrumentation differences at CROs, inconsistent aseptic technique, and analyst variability frequently leading to unexpected failures after transfer. These breakdowns can delay development timelines and introduce unnecessary regulatory risk.
The industry is actively searching for more reliable transfer strategies, tiered approaches to assay validation, stronger data driven QC controls, and more adaptable CRO partnerships. As ADC modalities become more complex, the fragility of poorly transferred assays becomes increasingly unsustainable, making this a central theme for 2026’s agenda.
Payload Instability & Degradation Identification Remain Deep Analytical Blind Spots
Several developers emphasized the technical difficulty of working with highly unstable payloads. Many next generation payloads degrade even at –20°C, are highly light sensitive, and generate numerous unidentified degradation fragments. Detecting these fragments is often complicated by the dominance of the antibody’s intact mass signal in MS readouts.
In parallel, there is a widespread lack of software tools capable of confidently interpreting small molecule degradants embedded within large molecule datasets. This analytical blind spot slows development of certain payload classes and increases uncertainty around stability and safety assessment. As novel payload chemistries proliferate, improved degradation mapping and detection strategies have become essential, and this need is reflected in this year’s agenda.
DAR Measurement, Distribution Profiling, & High DAR Toxicity Are Becoming Central Analytical Challenges
Drug to Antibody Ratio analysis has become one of the most frequently cited analytical bottlenecks. Traditional hydrophobic interaction chromatography methods often suffer from poor resolution, and the high salt conditions required for HIC are incompatible with direct MS coupling for peak identification. As a result, accurately profiling DAR distributions rather than relying solely on average DAR remains challenging.
The situation is further complicated by dual payload constructs, hydrophilic linkers, and branched chemistries, all of which increase distribution complexity. Experts also raised concerns about high DAR molecules, particularly in the DAR 8–12 range, potentially increasing toxicity and narrowing therapeutic index. Demonstrating clear correlations between DAR and potency remains difficult, and there is little alignment on acceptable DAR ranges for clinical programs. This makes DAR analysis one of the most technically demanding areas in ADC analytics today.
Conjugation Strategy and Analytical Requirements Are Becoming Inseparable in Next Generation ADCs
Changes in conjugation chemistry now directly dictate analytical strategy. Developers repeatedly stressed that analytical plans must be designed in parallel with conjugation approaches rather than retrofitted downstream. Determining DAR for branched linkers versus site specific conjugation, identifying which payload is preferentially lost under stress in dual payload constructs, and managing emerging impurity profiles all require integrated thinking between chemistry and analytics.
Ensuring that analytical methods remain robust across diverse conjugation topologies has become increasingly complex. This expanding interdependence between upstream design and downstream characterization has, in turn, shaped how the Summit brings together discovery and CMC stakeholders within unified strategic discussions.
Charge Variant Analysis Is Increasingly Unreliable for ADCs, Yet Still Expected by Regulators
Traditional charge variant methods developed for monoclonal antibodies often fail when applied to ADCs due to the dominant influence of hydrophobic payloads on overall charge distribution. Experts reported difficulty resolving meaningful charge differences post conjugation, even though regulatory agencies frequently continue to expect conventional charge variant profiles.
There is also pressure to control charge variants earlier in development, sometimes at the DSI level, despite limited confidence in the interpretability of the data. Uncertainty remains around whether alternative analytical strategies will be accepted in late-stage filings, creating hesitation around innovation. These challenges have sparked strong interest in exploring new approaches to charge variant analysis in this year’s discussions.
Comparability Studies Have Become a Grey Zone with High Analytical & Regulatory Burden
Comparability remains a persistent and complex challenge, particularly for companies undergoing manufacturing changes or scale transitions. Experts described ambiguous regulatory expectations regarding when comparability studies must be conducted and how extensive the analytical package should be. There is often limited clarity on which attributes are most critical and how deep characterization must go to satisfy regulators.
Interest is growing in AI enabled comparability assessments that leverage historical datasets to strengthen confidence while reducing unnecessary analytical repetition. However, regulatory acceptance of such approaches remains uncertain. The demand for more predictable and efficient comparability frameworks significantly influenced this theme’s inclusion in the 2026 Summit agenda.
Why These Themes Matter Now
Together, these insights reflect a field undergoing rapid maturation and unprecedented analytical complexity. ADC developers are no longer struggling primarily with payload potency or linker chemistry, but increasingly with analytical interpretation, regulatory risk management, and method reliability.
Innovation in analytical development is now judged by its ability to reduce impurity driven risk, provide mechanistic clarity around degradation pathways, support complex next generation constructs, improve DAR accuracy and interpretability, enable robust method transfer, and provide regulators with sufficient confidence for late-stage filings.
The 2026 agenda for the 5th ADC Analytical Development Summit has been built directly around these priorities, with a sharper focus than ever before on real-world implementation, regulatory credibility, and analytical robustness.